Uncategorized - May 12, 2015
Portable Device IDs Osteoporosis
Bindex, a pocket-sized diagnostic device for osteoporosis developed by the Kuopio medical device manufacturer Bone Index, shows measurement accuracy that meets international requirements, according to a recent medical study, and it could be recommended for use in primary health care offices. The results of a large international study were published at the World Congress on […]
In a new job - May 12, 2015
Oasmia Names Mikael Asp CEO
Mikael Asp has been appointed the new CEO of Oasmia pharmaceutical company. He succeeds Julian Aleksov, who has been nominated as the company’s new chairman of the board of directors. Current Board President Joel Lemon announced that he wishes to resign. Asp currently is head of quality assurance at the company and has many years […]
Clinical Trials - May 11, 2015
BerGenBio Cancer Drug in US Trial
A multi-center open label Phase 1b trial of BerGenBio AS’s BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway. The study is conducted at the University of Texas MD Anderson Cancer Center, […]
Clinical Trials - May 11, 2015
Saxenda Benefits Beyond Weight Loss
New data from a post-hoc analysis of the phase 3a SCALE™ clinical trial program were presented at the European Congress on Obesity (ECO), demonstrated that Novo Nordisk’s Saxenda (liraglutide 3 mg) has benefits beyond weight loss. “…The post-hoc analysis confirmed that weight loss has a positive impact on a number of cardiometabolic risk factors, including […]
Collaboration - May 11, 2015
Recipharm, LIDDS Talk Collaboration
Recipharm has begun negotiations with the pharmaceutical company LIDDS about collaborating on making Liproca Depot® ahead of continued clinical development and a potential future market launch. The companies explained in a joint letter their intention to initiate collaboration in the areas of scale-up, manufacture and quality assurance of LIDDS’ pharmaceutical products. Initially the companies will […]
Collaboration - May 11, 2015
Biobank Could Help Diamyd with Diabetes Vaccine
Diamyd, which is developing a vaccine against type 1 diabetes, now owns 39 percent of Cellaviva, Sweden’s first commercial biobank for stem cells. Diamyd made the investment because of the potential resource for research. “We believe in stem cells. Among other things, we hope that in the future we will be able to use them […]
